RELT Inhibitors
Chemical inhibitors of RELT can impede its signal transduction pathways through various molecular interactions. NF-κB Inhibitor, BAY 11-7082, Wedelolactone, Parthenolide, SN50, and TPCA-1 are chemicals that target the NF-κB pathway, which is crucial for the transcriptional activity following RELT activation. NF-κB Inhibitor and BAY 11-7082 act by preventing the activation of NF-κB itself, thereby directly reducing the transcription of NF-κB-responsive genes. Wedelolactone and TPCA-1 inhibit IKK, a kinase that is pivotal for the phosphorylation and subsequent degradation of IκB, an inhibitor of NF-κB. This degradation is necessary for the release and nuclear translocation of NF-κB; therefore, these inhibitors maintain NF-κB in an inactive state. SN50 impedes the nuclear translocation of NF-κB, effectively curtailing its ability to modulate gene expression. Parthenolide also disrupts NF-κB activation, though its precise mechanism within the RELT signaling context is focused on the suppression of the transcription factor's activity.
In addition to the NF-κB pathway, other signaling routes are modulated by RELT, such as the MAPK pathways, including ERK, JNK, and p38 MAPK. SP600125 interrupts the JNK pathway by preventing the kinase's activation, which is necessary for the phosphorylation of various transcription factors involved in RELT signaling. U0126 and PD98059 both serve as inhibitors of MEK, an upstream kinase in the MAPK/ERK pathway. By inhibiting MEK, these chemicals reduce the phosphorylation and activation of ERK, which is implicated in RELT-mediated cellular responses. SB203580 specifically targets p38 MAPK, another MAPK pathway component, to diminish the influence of RELT on p38 MAPK-regulated processes. LY294002 intervenes in the PI3K-Akt pathway associated with RELT signaling. By inhibiting PI3K, LY294002 prevents the activation of downstream targets such as Akt, thus attenuating the effects of RELT on those targets. Each chemical inhibitor operates through distinct mechanisms but converges on the inhibition of RELT's capacity to propagate its signal and elicit cellular responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is involved in the RELT signaling pathway. By inhibiting JNK, it can prevent the phosphorylation and activation of transcription factors that are downstream of RELT signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K is associated with the RELT signaling cascade and its inhibition can impede the activation of downstream targets of RELT, such as Akt, leading to decreased RELT-mediated cellular responses. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 acts as an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. RELT has been shown to interact with members of the MAPK pathway, and inhibition of MEK can thus prevent RELT from exerting its effects on ERK-mediated transcriptional events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, which plays a role in the signaling pathways utilized by RELT. Inhibition of p38 MAPK can reduce RELT's ability to influence inflammatory responses and other cellular processes mediated by this kinase. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 irreversibly inhibits NF-κB activation, which is crucial for RELT signaling. By preventing NF-κB activation, it impedes the transcription of genes that are activated in response to RELT engagement. | ||||||
[4-[(4-Benzo[b]thien-2-yl-2-pyrimidinyl)amino]phenyl][4-(1-pyrrolidinyl)-1-piperidinyl]-methanone | 873225-46-8 | sc-503387 | 10 mg | $430.00 | ||
This chemical inhibits IKK, which is necessary for NF-κB activation, a key pathway engaged by RELT. Inhibition of IKK consequently leads to a reduction in RELT-associated NF-κB-mediated transcriptional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. RELT can activate this pathway, and by inhibiting MEK, PD98059 can prevent the downstream effects of RELT activation. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $110.00 $337.00 | 8 | |
Wedelolactone is an inhibitor of IKK, and by this action, it can inhibit the NF-κB pathway. Since NF-κB is a key pathway for RELT signaling, wedelolactone can suppress the functional activity of RELT. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $81.00 $306.00 | 32 | |
Parthenolide inhibits NF-κB, a transcription factor that is a downstream target of RELT signaling. This inhibition can prevent the gene transcription that is normally initiated upon RELT activation. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 is an inhibitor of IKK-2, which is involved in NF-κB activation. By inhibiting IKK-2, TPCA-1 can disrupt RELT-mediated NF-κB signaling and subsequent gene expression. | ||||||